Results 141 to 150 of about 79,327 (229)

Peptides as a Therapeutic Alternative Against Leishmaniasis: A Scoping Review

Chemical Biology &Drug Design, Volume 107, Issue 5, May 2026.
This scoping review of 79 studies identified 231 antimicrobial peptides with anti‐Leishmania activity, including natural‐derived and synthetic peptides (inspired by natural sources or developed through rational design). Most were evaluated in vitro against promastigote and/or amastigote forms, with synthetic peptides showing a more promising effect ...
Maria Eduarda da Veiga Oliveira, Ellen Dyminski Parente Ribeiro, Otávio Henrique Pradi Guenther, Fernanda Tomiotto‐Pellissier   +3 more
wiley   +1 more source

A new malaria vaccination tool based on replication-competent Plasmodium falciparum parasites

EMBO Molecular Medicine
Recently licensed subunit vaccines represent the first and, thus far, the only approved agents for vaccination against malaria. However, these vaccines still fail to confer highly effective long-lasting protective immunity.
Diana Moita, Miguel Prudêncio
doaj   +1 more source

Malaria vaccination and rebound malaria [PDF]

The Lancet Infectious Diseases, 2019
Dicko, Alassane, Greenwood, Brian
openaire   +2 more sources

Advancing Pharmacoequity in Low‐ and Middle‐Income Countries via Model Informed Drug Development

Clinical and Translational Science, Volume 19, Issue 5, May 2026.
ABSTRACT Across low‐ and middle‐income countries (LMICs) inequities in access to safe, effective medicines persist due to limited regulatory capacity, inadequate financing, and insufficient local data. Regulatory authorities are engaging with model‐informed drug development (MIDD), but uneven technical readiness and resource gaps limit uptake ...
Henry Enzama, Francis Williams Ojara, Ian S. Haworth, Sandra Cvijic, Catriona Waitt, Thaddeus H. Grasela   +5 more
wiley   +1 more source

Immune mechanisms targeting malaria transmission: opportunities for vaccine development

Expert Review of Vaccines
Introduction Malaria continues to remain a major global health problem with nearly a quarter of a billion clinical cases and more than 600,000 deaths in 2022.
Geetha P. Bansal, Nirbhay Kumar
doaj   +1 more source

Malaria Vaccines: Progress to Date. [PDF]

BioDrugs, 2023
Stanisic DI, Good MF.
europepmc   +1 more source

Advanced Purchase Commitments for a Malaria Vaccine: Estimating Costs and Effectiveness [PDF]

To overcome the problem of insufficient research and development (R&D) on vaccines for diseases concentrated in low-income countries, sponsors could commit to purchase viable vaccines if and when they are developed. One or more sponsors would commit to a
Ernst R. Berndt, Georg Weizsacker, Heidi Williams, Jean Lee, Michael R. Kremer, Rachel Glennerster, Ruth Levine   +6 more
core  

Current approaches to malaria vaccines. [PDF]

Curr Opin Microbiol, 2022
Duffy PE.
europepmc   +1 more source

B and T cell responses to pre-erythrocytic R21/Matrix-M and blood-stage RH5.1/Matrix-M malaria vaccines in endemic settings. [PDF]

Front Immunol
Bundi CK, Muñoz O, Kibwana E, Bellamy D, Stockdale L, Barrett JR, McHugh K, Mtaka I, Kalinga W, Kimani D, Nyamako L, Keter K, Ogwang R, Hill AVS, Bejon P, Hamaluba M, Silk SE, Minassian AM, Draper SJ, Olotu AI, Kapulu MC, Ewer KJ, Nielsen CM.   +22 more
europepmc   +2 more sources

Malaria vaccines: Current developments and immunological insights. [PDF]

New Microbes New Infect
Verma A, Ranjha R, Singh K, Yadav V, Bhaskar A, Dwivedi VP, Mohan M.   +6 more
europepmc   +1 more source